2024-07-25 14:45:00
Days after announcing a licensing agreement with Foreseen Biotechnology, Ipsen continues to focus on oncology as one of its priority areas. The laboratory just announced a partnership with Day One to acquire regulatory and commercial rights to toborafenib outside the United States.
An active ingredient that offers hope for pediatric cancer
Toborafenib, marketed under the trade name Ojemda, is administered orally once weekly and is indicated for the treatment of children with low-grade glioma (GBG), the most common childhood brain cancer. As an inhibitor of the RAF gene, the drug has received orphan drug status because treatment options for this pathology remain limited. Following positive results in Phase II trials, Ojemda received accelerated approval from the FDA in April last year and can be marketed in the United States for the treatment of patients with GBG caused by RAF mutations. It remains the subject of Phase III studies as part of a confirmatory trial designed to verify and accurately characterize its clinical benefit.
Under the terms of the agreement, Day One will receive an upfront payment of approximately $111 million and may receive up to $350 million in milestone payments and royalties related to sales of toborafenib. Day One will continue to ensure the development and marketing of the drug in the United States.
Encouraging first-half results driven by oncology
The licensing of toborafenib is a strategic addition to Ipsen’s oncology portfolio, and the company has just reported first-half 2024 results. % % (compared to 6% at the beginning of the year).
The pharma giant’s good performance was mainly driven by sales of Cabometyx (cabotinib) and Dysport (abobotulinumtoxinA), as well as sales of Bylvay (odevixibat) and Onivyde (irinotecan), approved in the United States for first-line treatment of pancreatic cancer. . Another drug authorized by the FDA in 2024 is Iqirvo (elafibranor) for the treatment of primary biliary cholangitis. ” Across oncology, rare diseases and neuroscience, we now have a comprehensive portfolio of medicines, with new medicines launching this year in key indications ”, promised Ipsen CEO David Loew
To continue its growth trajectory, Ipsen also recently expanded its oncology collaborations with Exelixis and Marengo Therapeutics,” During the remainder of the year, we remain focused on product launches and commercial execution, as well as other opportunities to expand our portfolio in research and development » David Love concluded confidently.
1722233516
#Ipsen #continues #progress #oncology #revise #targets
